The impact of changing from ocrelizumab to ofatumumab on disease activity, infection and immunological parameters in patients with multiple sclerosis

被引：0
|
作者：
Montague, Turlough [1 ]
Chatterton, Sophie [1 ]
Cheung, Emily [1 ]
Thomas, Karen [1 ]
Simpson-Burke, Nicole [1 ]
Markoulis, Katherine [1 ]
Miller, Celia [1 ]
Fontes-Villalba, Ariadna [1 ]
Parratt, John [1 ]
机构：
[1] Royal North Shore Hosp, Sydney, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1715/1624
引用
收藏
页码：1084 / 1084
页数：1
相关论文
共 50 条
  • [1] Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab
    Meuth, Sven G.
    Wolff, Stephanie
    Mueck, Anna
    Willison, Alice
    Kleinschnitz, Konstanze
    Raeuber, Saskia
    Pawlitzki, Marc
    Konen, Franz Felix
    Skripuletz, Thomas
    Grothe, Matthias
    Ruck, Tobias
    Huttner, Hagen B.
    Kleinschnitz, Christoph
    Bopp, Tobias
    Pul, Refik
    Cree, Bruce A. C.
    Hartung, Hans-Peter
    Moellenhoff, Kathrin
    Pfeuffer, Steffen
    ANNALS OF NEUROLOGY, 2024,
  • [2] Immunological assessment in multiple sclerosis patients treated with ocrelizumab
    Mazziotti, V.
    Dapor, C.
    Marastoni, D.
    Crescenzo, F.
    Colombi, A.
    Pezzini, F.
    Calabrese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 582 - 582
  • [3] Switching from ocrelizumab to ofatumumab in multiple sclerosis: a monocenter real-world experience
    Axhausen, Franziska
    Baumgart, Romy
    Winter, Pia
    Mueck, Anna
    Huttner, Hagen
    Wolff, Stephanie
    Pfeuffer, Steffen
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1099 - 1100
  • [4] COST-EFFECTIVENESS OF OFATUMUMAB VERSUS OCRELIZUMAB IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
    Goncalves, N.
    Esparteiro, J.
    Machado, M.
    Ferreira, C.
    Guerreiro, T.
    VALUE IN HEALTH, 2022, 25 (12) : S78 - S78
  • [5] Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study
    Friedli, Christoph
    Krajnc, Nik
    Hammer, Helly N.
    Marti, Stefanie
    Zrzavy, Tobias
    Evangelopoulos, Maria E.
    Kapsali, Ioanna
    Rommer, Paulus
    Berger, Thomas
    Chan, Andrew
    Bsteh, Gabriel
    Hoepner, Robert
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2024, 16
  • [6] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, E.
    Schoof, L.
    Hogenboom, L.
    Wessels, M.
    van Ruyven, P.
    van Samkar, A.
    Mostert, J.
    van Kempen, Z.
    van Oosten, B. W.
    Wokke, B. H.
    Tallantyre, E.
    Myhr, K. M.
    Torkildsen, O.
    Killestein, J.
    Smets, I.
    Strijbis, E.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [7] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, Eline
    Schoof, Lisa
    Hogenboom, Laura
    Wessels, Mark
    van Ruyven, Paula
    van Samkar, Anusha
    Mostert, Jop
    van Kempen, Zoe
    van Oosten, Bob
    Wokke, Beatrijs
    Tallantyre, Emma
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    Killestein, Joep
    Smets, Ide
    Strijbis, Eva
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1063 - 1064
  • [8] Profile of multiple sclerosis patients on treatment with ocrelizumab and socio-economic impact of the disease
    Barbov, I.
    Boskova, T.
    Kuzmanovski, I.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 299 - 299
  • [9] Impact of Ocrelizumab on Immunoglobulin Levels and Infection Incidence: Navigating Treatment Adjustments in Multiple Sclerosis Patients
    Turkok, Cansu Gulcihan
    Yadi, Feyzullah
    Tezer, Damla Cetinkaya
    Dogan, Ipek Gungor
    Demir, Serkan
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1022 - 1023
  • [10] Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
    Maier, Smaranda
    Hutanu, Adina
    Barcutean, Laura
    Sarmasan, Emanuela
    Balasa, Rodica
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2024, 32 (03): : 245 - 254
12345